Progyny, Inc.
PGNY
Positions held
Your positionsPGNY isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Progyny operates in the growing healthcare plans industry, which is increasingly focusing on personalized and comprehensive fertility benefits, positioning itself as a leader in this niche market.
- In Q2 2026, Progyny reported a revenue of $350.511 million, reflecting a 7% increase compared to the previous quarter.
- The company's gross margin improved to 25.5% in Q2 2026, up from 25.3% in the prior quarter.
- Despite its growth, Progyny's high debt-to-equity ratio of 5.95 raises concerns about financial stability and risk management.
- The operating margin for Q4 2025 was only 4.78%, indicating potential inefficiencies in cost management.
- Progyny's trailing P/E ratio stands at 28.16, suggesting that the stock may be overvalued compared to its earnings growth potential.
Fundamentals
| Market cap | $2.14B | Enterprise value | $1.93B | Trailing P/E | 30.25 | Forward P/E | 12.00 |
| PEG | — | Price / book | 4.71 | Beta | 1.02 | Dividend yield | 0.00% |
| Revenue growth | 5.3% | Earnings growth | 78.9% | Gross margin | 24.6% | Operating margin | 11.4% |
| Profit margin | 6.0% | ROE | 16.2% | ROA | 10.1% | Debt / equity | 0.06 |
| Current ratio | 2.14 | Free cash flow | $196.47M | Analyst recommendation | strong_buy | Mean target | $34.42 |
| 52w high | $33.07 | 52w low | $16.10 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $351M | $329M | $318M | $313M | $333M |
| Op margin | 11.4% | 10.8% | 4.8% | 6.9% | 7.3% |
| Net income | $28.1M | $24.2M | $12.5M | $13.9M | $17.1M |
| Gross margin | 25.5% | 25.3% | 24.1% | 23.2% | 23.7% |
| Gross profit | $89.3M | $83.1M | $76.9M | $72.8M | $79.0M |
| Operating income | $40.0M | $35.4M | $15.2M | $21.5M | $24.4M |
- Revenue +7% vs prior quarter ($351M vs $329M).
- Gross margin 25.5% (was 25.3% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.3B | $1.2B | $1.1B | $787M | — |
| Op margin | 6.6% | 5.8% | 5.7% | 3.0% | — |
| Net income | $58.5M | $54.3M | $62.0M | $30.4M | — |
| Gross margin | 23.6% | 21.7% | 21.9% | 21.3% | — |
| Gross profit | $304M | $253M | $239M | $167M | — |
| Operating income | $85.3M | $67.5M | $62.2M | $23.3M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Progyny (PGNY) Soars 6.3%: Is Further Upside Left in the Stock?
2026-10-07 · Why Are Progyny (PGNY) Shares Soaring Today
2026-10-07 · Progyny Sees Record Employer Signups, Adding 1.2 Million to Coverage
2026-10-07 · PGNY or CRL: Which Is the Better Value Stock Right Now?
2026-10-07 · Progyny, Inc. Selling Season Pacing to Record Level, Revealing Critical Insights on Latest Market Dynamics
2026-09-24 · 3 Profitable Stocks with Warning Signs
2026-09-18 · PGNY vs. CRL: Which Stock Is the Better Value Option?
2026-09-18 · Progyny (PGNY) Stock Looks Fairly Valued Despite Its 57% Five Year Slide
2026-09-15 · Concentra Group Holdings Parent, Inc. (CON) Hits Fresh High: Is There Still Room to Run?
2026-09-14 · Progyny Insider Sold Shares Worth $321,358, According to a Recent SEC Filing
2026-09-10 · Spotting Winners: Progyny (NASDAQ:PGNY) And Health Insurance Providers Stocks In Q2
2026-09-09 · Wall Street Analysts Predict a 25.23% Upside in Progyny (PGNY): Here's What You Should Know
Price (daily)
Full chart · RSI · MACD · patterns